Patterns of Drug Use among Patients with Dyspepsia at UPT Puskesmas Sekura in 2026

Authors

  • Syarifah Nayla Fitriya Yarsi Pharmacy Academy of Pontianak, Indonesia
  • Dani Suryaningrat Yarsi Pharmacy Academy of Pontianak, Indonesia

DOI:

https://doi.org/10.33394/hjkk.v14i5.22661

Keywords:

Dyspepsia, Drug Utilization Pattern, Antacid, Ranitidine, Omeprazole

Abstract

Dyspepsia is a group of symptoms affecting the upper gastrointestinal tract and remains a health concern requiring appropriate pharmacological management. Sekura Community Health Center has a relatively high number of dyspepsia cases; however, information regarding medication utilization patterns among patients with dyspepsia remains limited. This study aimed to describe medication utilization patterns among patients with dyspepsia at Sekura Community Health Center from January to June 2026. This descriptive observational study employed a retrospective approach using prescription and/or medical records of patients diagnosed with dyspepsia during the study period. Total sampling included 741 patients who met the study criteria. Data were analyzed descriptively and presented in tables, diagrams, and narrative descriptions. Dyspepsia cases were most frequently observed among patients aged 46–65 years (300 patients, 40.49%) and female patients (484 patients, 65.32%). The medications recorded were DOEN antacids, ranitidine, and omeprazole, accounting for 35.63%, 34.28%, and 30.09% of medication use, respectively. During the study period, the recorded numbers of medication administration events were 264 for DOEN antacids, 254 for ranitidine, and 223 for omeprazole. These figures represent medication administration events rather than unique patients or prescriptions. The findings provide a descriptive overview of medication utilization at Sekura Community Health Center and may inform pharmaceutical service evaluation, particularly regarding prescription appropriateness, dosage accuracy, medication safety, and adherence to current clinical guidelines. Further research is needed to assess treatment outcomes and factors influencing prescribing decisions.

References

Adisaputra, A. D., Arda, A., Masyita, A., Rizal, M., & Safarudin, R. (2026). Evaluation of the Rationality of Drug Use in Patients with Dyspepsia at Anutapura Palu Hospital, Indonesia. Mutiara Medika: Jurnal Kedokteran dan Kesehatan. https://doi.org/10.18196/mmjkk.v26i1.27577

Amengor, C., Akuffo, O. F. W., Kwaning, J., Iddrisu, A. H., Ohemeng, A., Acheampomaa, D. A., & Gyapong, P. (2020). Acid Neutralizing Capacity of Selected Antacid Suspensions Available in the Ghanaian Market. 10-15. https://doi.org/10.9734/ajrimps/2020/v9i230148

Andrawes, M., Andrawes, W., Das, A., & Siau, K. (2025). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. Medicina, 61. https://doi.org/10.3390/medicina61091569

Bottero, E., Benvenuti, E., Ferriani, R., Manassero, E., Re, G., & Barbero, R. (2020). Preliminary comparative serological evaluation of Histamine H2 receptors in dogs with an acute onset of vomiting treated with Ranitidine and healthy dogs. Veterinary and Animal Science, 10. https://doi.org/10.1016/j.vas.2020.100138

Boya, D., & Ahmed, J. (2021). Comparison of Acid-neutralizing capacity of antacids in Erbil City. Zanco Journal of Medical Sciences. https://doi.org/10.15218/zjms.2021.023

Cuzzolin, L., Locci, C., Chicconi, E., & Antonucci, R. (2023). Clinical use of gastric antisecretory drugs in pediatric patients with gastroesophageal reflux disease: a narrative review. Translational Pediatrics, 12, 260–270. https://doi.org/10.21037/tp-22-401

Dipasquale, V., Cicala, G., Spina, E., & Romano, C. (2022). A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.839972

Harer, K. N., & Hasler, W. (2020). Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options.. Gastroenterology & hepatology, 16 2, 66-74. https://doi.org/10.1201/b22811-11.

Herman, H., Wati, A., Alfiah, A., & Zahra, A. A. (2026). Analisis Efektivitas-Biaya Terapi Ppi, H2ra, Dan Kombinasi Pada Pasien Dispepsia Rawat Inap. As-Syifaa Jurnal Farmasi. https://doi.org/10.56711/jifa.v18i1.1515

Hutabarat, R. E., Harahap, D. W. S., & Ginting, A. N. B. (2026). Evaluasi Penggunaan Obat Pada Pasien Dispepsia Menggunakan Metode Atc/Ddd Di Rumah Sakit Royal Prima Tahun 2022. Jurnal Buana Farma. https://doi.org/10.36805/jbf.v6i1.1677

Jenkins, D., & Modolell, I. (2023). Proton pump inhibitors. BMJ, 383. https://doi.org/10.1136/bmj-2022-070752

Kim, Y. S., & Kim, N. (2020). Functional Dyspepsia: A Narrative Review With a Focus on Sex-Gender Differences. Journal of Neurogastroenterology and Motility, 26, 322 - 334. https://doi.org/10.5056/jnm20026

Lee, K.-J. (2021). The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents. Journal of Neurogastroenterology and Motility, 27, 326 - 336. https://doi.org/10.5056/jnm21042

Lee, K., Kwon, C.-I., Yeniova, A. Ö., Koyanagi, A., Jacob, L., Smith, L., Lee, S. W., Rahmati, M., Shin, J.-Y., Shin, J. I., Cho, W., & Yon, D. K. (2024). Global prevalence of functional dyspepsia according to Rome criteria, 1990–2020: A systematic review and meta-analysis. Scientific Reports, 14, 4172. https://doi.org/10.1038/s41598-024-54716-3

Marini, T., Afriyanti, U., Pramono, Y. S., & Hadrianti, D. (2025). Factors Associated with the Incidence of Dyspepsia in the Working Area of Teluk Tiram Public Health Center, Banjarmasin City. Papua Medicine and Health Science. https://doi.org/10.64141/pmhs.v2i1.27

Mulak, A., Freud, T., Waluga, M., Bangdiwala, S., Palsson, O., & Sperber, A. (2023). Sex‐ and gender‐related differences in the prevalence and burden of disorders of gut‐brain interaction in Poland. Neurogastroenterology & Motility, 35. https://doi.org/10.1111/nmo.14568

Nabila, H., Dewi, N. M. A. R., & Lestarini, I. A. (2022). Evaluasi pola penggunaan obat dispepsia berdasarkan indikator WHO (World Health Organization) pada pasien rawat jalan Puskesmas Karang Taliwang tahun 2019. Sasambo Journal of Pharmacy, 3(1), 11–17. https://doi.org/10.29303/sjp.v3i1.139

Notoatmodjo, S. (2018). Metodologi penelitian kesehatan. Rineka Cipta.

Puskesmas Sekura. (2026). Laporan Harian Penyakit UPT Puskesmas Sekura periode 1–31 Juli 2026. UPT Puskesmas Sekura.

Rahmatillah. (2024). Profil dan karakteristik penggunaan analgesik pada kasus myalgia di Puskesmas Soromandi. Hydrogen: Jurnal Kependidikan Kimia, 12(6). https://doi.org/10.33394/hjkk.v12i6.13866

Saboo, B., Mulwani, N., Petare, A., Veligandla, K., Pinto, C., Mane, A., Rathod, R., & Kotak, B. (2023). A real-world retrospective study of omeprazole–domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2). Drugs in Context, 12. https://doi.org/10.7573/dic.2022-10-3

Setiyawati, R., & Hastuti, D. (2021). Pola peresepan obat dispepsia pada pasien dewasa di Klinik Kimia Farma 275 Yogyakarta periode Januari–April 2019. Jurnal Kefarmasian Akfarindo, 6(1), 14–20. https://doi.org/10.37089/jofar.vi0.98

Shetty, B., & Vishwanath, M. K. (2022). An expert opinion on antacids: A review of its pharmacological properties and therapeutic efficacy. F1000Research. https://doi.org/10.12688/f1000research.124024.1

Siddique, A., Mannan, A., Rifaqat, M., & Singh, R. (2025). ROLE OF Histamine Type-2 Receptor Antagonists (H2 Blockers). International Journal on Science and Technology. https://doi.org/10.71097/ijsat.v16.i3.8365

Suherman, L. P., Islamiyah, A. N., Ahmad, M., Amelia, R., Septiani, V., Ramdani, R., & Indrawati, W. (2023). Pola penggunaan obat pada pasien dispepsia di Puskesmas Cimahi Tengah Kota Cimahi. Pharmacoscript, 6(2), 193–207. https://doi.org/10.36423/pharmacoscript.v6i2.1257

Suherman, L. P., Kartidjo, P., Rukmawati, I., Septiani, V., & Azzura, F. (2021). Dyspepsia Drug Use Pattern of Outpatients in a Public Health Center in Batununggal District Bandung. Borneo Journal of Pharmacy. https://doi.org/10.33084/bjop.v4i4.1987

Syafitri, N., Ramadhan, A. M., & Faisal, M. (2021). Evaluasi penggunaan obat pada pasien dispepsia di Rumah Sakit Samarinda Medika Citra tahun 2021. Proceeding of Mulawarman Pharmaceuticals Conferences, 14, 64–69. https://doi.org/10.25026/mpc.v14i1.572

Syam, A. F., Miftahussurur, M., Makmun, D., Abdullah, M., Rani, A. A., Siregar, G. A., Simadibrata, M., Zubir, N., Dewa Nyoman Wibawa, I., Purnomo, H. D., Manan, C., Djojoningrat, D., Fauzi, A., Renaldi, K., Maulahela, H., Utari, A. P., Pribadi, R. R., Muzellina, V. N., Nursyirwan, S. A., ... Yamaoka, Y. (2023). Management of dyspepsia and Helicobacter pylori infection: The 2022 Indonesian Consensus Report. Gut Pathogens, 15(1), 25. https://doi.org/10.1186/s13099-023-00551-2

Tack, J., Palsson, O., Bangdiwala, S., Schol, J., Carbone, F., Van Den Houte, K., Broeders, B., Drossman, D., Dumitrascu, D., Fang, X., Fukudo, S., Ghoshal, U., Kellow, J., Khatun, R., Okeke, E., Quigley, E., Schmulson, M., Simrén, M., Whitehead, W., . . . Sperber, A. (2025). Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study. Alimentary Pharmacology & Therapeutics, 62, 330 - 339. https://doi.org/10.1111/apt.70189

Trukhan, D., Degovtsov, E. N., & Novikov, A. (2023). Antacids in real clinical practice. Meditsinskiy sovet = Medical Council. https://doi.org/10.21518/ms2023-141

Vg, M. P., McFarland, L. V., Thacker, H., Puri, R., & Lawate, P. (2024). Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice. https://doi.org/10.1155/2024/9990554

Vanheel, H., Carbone, F., Valvekens, L., Simrén, M., Tornblom, H., Vanuytsel, T., Van Oudenhove, L., & Tack, J. (2016). Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. The American Journal of Gastroenterology, 112, 132-140. https://doi.org/10.1038/ajg.2016.499

Vara-Luíz, F., Mendes, I., Palma, C., Mascarenhas, P., Teles, A. E., Santos, I. C., Nunes, G., Patita, M., Mocanu, I., Pires, S., Meira, T., Vieira, A., Pinto-Marques, P., Gomes-Pinto, D., & Fonseca, J. (2025). Clinical, Endoscopic and Histologic Differences in Gastric Mucosa Between Younger and Older Adults: An Observational Study on the Aging Stomach. Medical Sciences, 13. https://doi.org/10.3390/medsci13040224

Wang, L., Shi, Y.-P., Li, Y.-N., Wang, X.-J., Xu, L.-J., & Zhang, Y. (2025). Pathophysiological mechanisms of functional dyspepsia: a narrative review. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1624242

Wauters, L., Dickman, R., Drug, V., Mulak, A., Serra, J., Enck, P., Tack, J., Accarino, A., Barbara, G., Bor, S., Coffin, B., Corsetti, M., De Schepper, H., Dumitrascu, D., Farmer, A., Gourcerol, G., Hauser, G., Hausken, T., Karamanolis, G., . . . Zerbib, F. (2021). United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. Neurogastroenterology & Motility, 33. https://doi.org/10.1111/nmo.14238

World Health Organization. (2024). Promoting rational use of medicines. World Health Organization.

Zhang, J.-J., & An, J. (2025). Updating understanding of real-world adverse events associated with omeprazole. PLOS One, 20. https://doi.org/10.1371/journal.pone.0330509

Zou, S., Ouyang, M.-L., Cheng, Q., Shi, X., & Sun, M. (2023). Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 44, 171–183. https://doi.org/10.1002/phar.2899

Published

2026-10-31

How to Cite

Fitriya, S. N., & Suryaningrat, D. (2026). Patterns of Drug Use among Patients with Dyspepsia at UPT Puskesmas Sekura in 2026. Hydrogen: Jurnal Kependidikan Kimia, 14(5). https://doi.org/10.33394/hjkk.v14i5.22661

Issue

Vol. 14 No. 5 (2026): October 2026

Section

Articles

License

Copyright (c) 2026 Syarifah Nayla Fitriya, Dani Suryaningrat

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

License and Publishing Agreement
In submitting the manuscript to the journal, the authors certify that:

  1. They are authorized by their co-authors to enter into these arrangements.
  2. The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
  3. That it is not under consideration for publication elsewhere,
  4. That its publication has been approved by all the author(s) and by the responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
  5. They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
  6. They agree to the following license and publishing agreement.

Copyright
Authors who publish with Hydrogen: Jurnal Kependidikan Kimia agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Licensing for Data Publication

Hydrogen: Jurnal Kependidikan Kimia uses a variety of waivers and licenses, that are specifically designed for and appropriate for the treatment of data: Open Data Commons Attribution License, http://www.opendatacommons.org/licenses/by/1.0/ (default) Other data publishing licenses may be allowed as exceptions (subject to approval by the editor on a case-by-case basis) and should be justified with a written statement from the author, which will be published with the article.